Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Cash from Operations (2022 - 2025)

Historic Cash from Operations for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to -$39.0 million.

  • Indivior Pharmaceuticals' Cash from Operations fell 205000.0% to -$39.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $177.0 million, marking a year-over-year increase of 17224.49%. This contributed to the annual value of $36.0 million for FY2024, which is 11200.0% up from last year.
  • Latest data reveals that Indivior Pharmaceuticals reported Cash from Operations of -$39.0 million as of Q3 2025, which was down 205000.0% from $158.0 million recorded in Q2 2025.
  • Indivior Pharmaceuticals' 5-year Cash from Operations high stood at $158.0 million for Q2 2025, and its period low was -$298.0 million during Q4 2023.
  • In the last 4 years, Indivior Pharmaceuticals' Cash from Operations had a median value of -$10.0 million in 2023 and averaged -$4.6 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first soared by 98000.0% in 2024, then crashed by 205000.0% in 2025.
  • Quarter analysis of 4 years shows Indivior Pharmaceuticals' Cash from Operations stood at -$18.0 million in 2022, then crashed by 1555.56% to -$298.0 million in 2023, then surged by 94.3% to -$17.0 million in 2024, then tumbled by 129.41% to -$39.0 million in 2025.
  • Its Cash from Operations stands at -$39.0 million for Q3 2025, versus $158.0 million for Q2 2025 and $75.0 million for Q1 2025.